- ISIN
- US0327241065
- CUSIP
- 032724106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 26, 2017
Highlights
- Market Cap
- $1.47B
- Enterprise Value
- $1.24B
- EPS (TTM)
- -$0.91
- Total Revenue (TTM)
- $232.39M
- Gross Profit (TTM)
- $245.59M
- EBITDA (TTM)
- $52.72M
- Year Range
- $11.40 - $72.36
- Target Price
- $77.29
- ROA (TTM)
- -8.13%
- ROE (TTM)
- -210.14%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ANAB Performance Chart
AnaptysBio, Inc. (ANAB) is up 58.5% since the beginning of the year. At $51 per share, ANAB is trading 29.2% below its 52-week high of $72. Investors who bought $1,000 worth of ANAB shares 5 years ago would now be looking at an investment worth $3,371.
Loading charts...
Returns By Period
AnaptysBio, Inc. (ANAB) has returned 58.54% so far this year and 226.79% over the past 12 months.
AnaptysBio, Inc.
- 1D
- -0.04%
- 1M
- -26.57%
- YTD
- 58.54%
- 6M
- 75.64%
- 1Y
- 226.79%
- 3Y*
- 60.13%
- 5Y*
- 27.51%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
ANAB Monthly Returns History
Based on dividend-adjusted daily data since Jan 26, 2017, ANAB's average daily return is +0.18%, while the average monthly return is +3.60%. At this rate, an investment would double in approximately 1.6 years.
Historically, 54% of months were positive and 46% were negative. The best month was Oct 2020 with a return of +99.7%, while the worst month was Nov 2019 at -64.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ANAB closed higher 50% of trading days. The best single day was Oct 10, 2017 with a return of +101.2%, while the worst single day was Nov 8, 2019 at -71.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.21% | 16.11% | 0.74% | 77.78% | -15.31% | -7.96% | 58.54% | ||||||
| 2025 | 35.42% | -6.19% | 10.52% | 19.53% | 0.05% | -0.13% | 10.59% | -17.19% | 50.61% | 19.46% | 13.86% | 16.40% | 266.16% |
| 2024 | 10.18% | 8.18% | -11.79% | 8.08% | -1.64% | 4.68% | 39.03% | 9.33% | -12.05% | -35.43% | 15.40% | -46.96% | -38.19% |
| 2023 | -19.68% | 0.04% | -12.61% | -4.32% | -8.26% | 6.49% | -3.10% | -0.15% | -8.74% | -9.19% | -13.30% | 51.49% | -30.88% |
| 2022 | -8.00% | -4.38% | -19.07% | -5.42% | -18.85% | 6.90% | 3.15% | 10.89% | 9.86% | 13.09% | -4.23% | 12.16% | -10.82% |
| 2021 | 20.56% | 10.73% | -24.91% | 8.35% | 2.23% | 8.63% | -11.38% | 11.44% | 5.90% | 21.31% | -1.67% | 7.42% | 61.63% |
Benchmark Metrics
AnaptysBio, Inc. has an annualized alpha of 37.20%, beta of 0.98, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since January 27, 2017.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (71.30%) than losses (40.05%) - typical of diversified or defensive assets.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 37.20%
- Beta
- 0.98
- R²
- 0.06
- Upside Capture
- 71.30%
- Downside Capture
- 40.05%
Return for Risk
Risk / Return Rank
ANAB ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AnaptysBio, Inc. (ANAB) and compare them to S&P 500 Index.
| ANAB | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.24 | 2.24 | +1.00 |
Sortino ratioReturn per unit of downside risk | 3.63 | 3.07 | +0.56 |
Omega ratioGain probability vs. loss probability | 1.48 | 1.41 | +0.08 |
Calmar ratioReturn relative to maximum drawdown | 8.11 | 2.93 | +5.18 |
Martin ratioReturn relative to average drawdown | 20.93 | 13.52 | +7.41 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the AnaptysBio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AnaptysBio, Inc. was 92.08%, occurring on Nov 8, 2019. The portfolio has not yet recovered.
The current AnaptysBio, Inc. drawdown is 40.21%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2019 bear market2019 | -92.08%Nov 2019 | 1y 8mo | — | 8y 3moMar 2018 - now |
2017 bear market2017 | -32.97%Jun 2017 | 2mo 8d | 1mo 17d | 3mo 25dMar 2017 - Jul 2017 |
2017 bear market2017 | -32.31%Aug 2017 | 21d | 22d | 1mo 13dJul 2017 - Sep 2017 |
2018 correction2018 | -14.04%Feb 2018 | 11d | 9d | 20dJan 2018 - Feb 2018 |
2017 correction2017 | -10.40%Oct 2017 | 5d | 26d | 1mo 1dOct 2017 - Nov 2017 |
Drawdown Indicators
| ANAB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.08% | -56.78% | -35.30% |
Max Drawdown (1Y)Largest decline over 1 year | -28.15% | -9.10% | -19.05% |
Max Drawdown (3Y)Largest decline over 3 years | -69.32% | -18.90% | -50.42% |
Max Drawdown (5Y)Largest decline over 5 years | -69.32% | -25.43% | -43.89% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -40.21% | -0.74% | -39.47% |
Average DrawdownAverage peak-to-trough decline | -64.74% | -10.72% | -54.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.92% | 1.97% | +8.95% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AnaptysBio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AnaptysBio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ANAB relative to other companies in the Biotechnology industry. Currently, ANAB has a P/S ratio of 6.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ANAB in comparison with other companies in the Biotechnology industry. Currently, ANAB has a P/B value of 115.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ANAB
Add AnaptysBio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ANAB